For FH patients with LDLR, APOB, and PCSK9 mutations, the time interval for the occurrence of new cardiovascular events was significantly decreased, compared to FH patients without mutations (14 months vs. 27 months, p = 0.001) (Figure 6a). This evidence concerns the gene PCSK9 and familial hyperaldosteronism.